Randomized, double-blind, placebo-controlled phase IIb clinical trials indicated that sifalimumab, an anti-IFNα monoclonal antibody [58], and anifrolumab, a type I IFN receptor antagonist [59], positively impacted lupus symptoms. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.